Updates are available Correction dated 2022-09-05
Click to view Correction: https://doi.org/10.1186/s12969-022-00736-0
-
Authors
Nishi, Kentaro
Ogura, Masao
Tamai, Naotaka
Gima, Masafumi
Ide, Kentaro
Koinuma, Goro
Kamei, Koichi
Ito, Shuichi https://orcid.org/0000-0002-5242-8987
- License Information
-
More Information
Article History
Received: 3 February 2022
Accepted: 11 July 2022
First Online: 4 August 2022
Change Date: 5 September 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12969-022-00736-0
Declarations
:
: Ethics approval was not applicable. Informed consent was obtained from the patient. The use of rituximab was approved by the institutional ethics committee of the National Center for Child Health and Development (approval no. 2020–03).
: Consent for publication was obtained from the patient’s guardian. Written informed consent was obtained from the legal guardians as the patient was aged < 16 years. This was applicable for all potentially identifiable information contained within the manuscript file and is available for review by the editor of the journal.
: There was no external funding for this manuscript. Koichi Kamei received research funding from the Terumo Foundation for Life Sciences and Arts and donations from Ono Pharmaceutical Co., Ltd. Shuichi Ito received employment from TEIJIN PHARMA Ltd., Honoraria from SANOFI K.K., and research funding from TEIJIN PHARMA Ltd. and Astellas PHARMA Co., Ltd. The other authors have no potential conflicts of interest to disclose.
